Clinical trialNCT04579757TerminatedPhase 1/PHASE2Interventional

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

SponsorHutchmedEnrollment87Anaplastic Thyroid CancerColorectal CancerGastric CancerMetastatic Solid TumorNeuroendocrine TumorsSmall Cell Lung Cancer+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

William Schelman, MD
Hutchmed
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Arizona Oncology Associated, Pc-Hope
Tucson, Arizona, United States
City of Hope
Duarte, California, United States
Rocky Mountain Cancer Centers Midtown
Denver, Colorado, United States
Johns Hopkins University - Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
Holden Comprehensive Cancer Center, University of Iowa
Iowa City, Iowa, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
University of Pennsylvania, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Prisma Health - Upstate (itor)
Greenville, South Carolina, United States
Sarah Cannon
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology, P.A.
Fort Worth, Texas, United States
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Texas Oncology, P.A.
Tyler, Texas, United States
Virginia Cancer Specialists, Pc
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Surufatinib and Tislelizumab _ Part 1Surufatinib and Tislelizumab _ Part 2

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Mar 2021
Primary completion: 30 Apr 2024
Completion: 27 Aug 2024
Last update posted: 8 May 2025
Registered enrollment: 87
Registry id: NCT04579757

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.